Sense Biodetection has received the CE Mark for its Veros COVID-19 molecular diagnostic test, enabling the company to market the assay in European countries that recognize the certification.
Designed to provide results in 15 minutes at a performance comparable to polymerase chain reaction diagnostic technology, Veros COVID-19 is suitable for use in environments such as hospital emergency departments, pharmacies, care homes, and urgent care, according to Sense. In a multicenter trial, the IVD test yielded an accuracy rate of 97.9%, Sense said.
Sense plans to launch Veros COVID-19 in Europe this quarter beginning in Ireland, Benelux, and the Nordic regions.
